Abstract: Transforming growth factor-b (TGF-b) is a multifunctional cytokine that induces growth arrest, tissue brosis, and epithelial-mesenchymal transition (EMT) through activation of Smad and non-Smad signaling pathways. EMT is the dierentiation switch by which polarized epithelial cells dierentiate into contractile and motile mesenchymal cells. Cell motility and invasive capacity are activated upon EMT. Multiple transcription factors, including dEF1/ZEB1, SIP1/ZEB2, and Snail/SNAI1, are induced by TGF-b{Smad signaling and play critical roles in TGF-b-induced EMT. In addition, both non-Smad signaling activated by TGF-b and cross-talk with other signaling pathways play important roles in induction of EMT. Of these, Ras signaling synergizes with TGF-b-Smad signaling, and plays an important role in the induction of EMT. TGF-b inhibitors prevent invasion and metastasis of advanced cancer through multiple mechanisms, including inhibition of EMT. The discovery of molecules that inhibit TGF-b-induced EMT but not TGF-b-induced growth arrest may be an ideal strategy for treatment of invasion and metastasis of cancer.
Introduction
Transforming growth factor-b (TGF-b) is a multifunctional cytokine that potently inhibits the proliferation of most types of cells, including epithelial cells, endothelial cells, hematopoietic cells, and lymphocytes. 1) TGF-b also induces tissue brosis through induction of various extracellular matrix proteins. Recently, numerous studies have revealed that TGF-b stimulates epithelial-mesenchymal transition (EMT) in certain epithelial cells. 2) TGF-b has thus been found to have bidirectional functions in the progression of cancer: it acts as a tumor suppressor by inhibition of cell proliferation through repression of c-Myc expression and some cyclin-dependent kinase inhibitors, 3) while it functions as a pro-oncogenic factor through stimulation of matrix deposition, perturbation of immune function, and induction of EMT. 4) Recent ndings have shown that cancer cells, e.g. diuse-type gastric cancer cells, treated with TGF-b secrete an anti-angiogenic factor thrombospondin-1, and thus that TGF-b acts as an antioncogenic factor via eects on the tumor microenvironment. 5), 6) EMT is an important step in the invasion and metastasis of cancer, and TGF-b induces progression of cancer through EMT. TGF-b was originally discovered as a cytokine that induces anchorage-independent growth of normal broblasts in the presence of epidermal growth factor (EGF), 7) and TGF-binduced EMT-like activity was reported by many investigators even in the early 1990's. Welch et al. reported that treatment of mammary adenocarcinoma cells with TGF-b1 resulted in acceleration of lung metastasis in a xenograft model, due to increased capacity for extravasation and elevated expression of gelatinolytic activity. 8) Similarly, Meth A sarcoma cells expressing active TGF-b1 were shown to be more adhesive in vitro and more tumorigenic in vivo than parental cells. 9) Although levels of expression of epithelial and mesenchymal markers were not fully determined in these studies, it is most likely that TGF-b triggered EMT in these cancer cells, and thereby promoted invasion and metastasis of cancer.
EMT occurs in various settings during embryonic development, but is also tightly linked to the pathogenesis of certain disease processes, including progression of brosis and cancer. In addition to TGF-b, various extracellular factors, including bone morphogenetic proteins (BMPs), Wnt, Notch ligands, hepatocyte growth factor, platelet-derived growth factor, and broblast growth factor, induce EMT in a coordinated and/or sequential fashion. 2) Since the roles of EMT during embryonic development and progression of brosis have been discussed in other review articles, 2),10),11) I will focus my discussion on TGF-b-induced EMT in cancer progression in this review.
TGF-b activates Smad and non-Smad signaling pathways
TGF-b binds to type II and type I serine-threonine kinase receptors, termed TbRII and TbRI, respectively. 12),13) TbRII transphosphorylates TbRI, and the latter activates receptor-regulated Smads (R-Smads) (Fig. 1). 14) The R-Smads activated by TbRI or activin type I receptors are Smad2 and Smad3, while BMP type I receptors induce phosphorylation of Smad1, 5, and 8. 15) Activated RSmads form complexes with common-partner Smad (co-Smad; Smad4 in mammals), and translocate into the nucleus. 14) The R-Smad-co-Smad complexes interact with various transcription factors and transcriptional co-activators or co-repressors, and regulate transcription of target genes. 16),17) Smad7 is an inhibitory Smad (I-Smad), which inhibits TGF-b signaling through multiple mechanisms. 18) Importantly, Smad7 binds to activated type I receptors and competes with R-Smads for receptor binding, resulting in repression of TGF-b signaling. c-Ski and its related protein SnoN are transcriptional co-repressors, which inhibit the transcriptional activity of R-Smadco-Smad complexes through interaction with Smad2/ 3 as well as Smad4. 19) Expression of Smad7 and cSki, induced by TGF-b-Smad signaling, represses TGF-b signaling through negative feedback loops.
In addition to the Smad signaling pathways, TGF-b activates various types of non-Smad signaling in certain types of cells (Fig. 1) . Among them, it is reported that Erk, c-Jun N-terminal kinase (JNK), and p38 MAP kinases, phosphatidylinsitol-3 (PI3) kinase, and RhoA, Rac1, and Cdc42 GTPases play important roles in TGF-b-induced EMT. 2) 
Process of EMT
EMT is a process in which epithelial cells forming an organized, tightly connected sheet transdierentiate into disorganized motile mesenchymal cells (Fig. 2) . 2),10),11) EMT occurs in an orchestrated fashion; one of the earliest events in it involves the disruption of tight junctions that connect epithelial cells, as well as delocalization of tight junction proteins, including zonula occludens 1 (ZO-1), claudin 1, and occludin. Adherens junction complexes, which contain E-cadherin and b-catenin, are also disrupted, and reorganization of the actin cytoskeleton from a cortical location into actin stress bers anchored to the focal adhesion complexes is observed.
Upon EMT, apical-basal cell polarity is lost, and cells exhibit a spindle-shaped, broblast-like morphology and express mesenchymal markers, including N-cadherin, vimentin, bronectin, smooth muscle a-actin (SMA), and broblast-specic protein-1 (FSP1). 20) The resultant mesenchymal cells exhibit a phenotype with altered adhesive properties, increased secretion of extracellular proteases, and altered expression of extracellular matrix proteins and their receptors, leading to increased migratory and invasive capacity. 21) Cancer metastasis is accelerated by EMT through stimulation of cell migration and invasion, cell-substrate adhesion, intravasation, and extravasation, as well as cell survival. Indeed, cell survival is important for transit of tumor cells in the blood and lymph systems, and reestablishment at sites of metastasis. Metastasis is also accelerated through immunosuppression during EMT induced by the transcription factor Snail. 22) EMT may also accelerate tumor progression through production of cells in the tumor microenvironment, such as cancerassociated broblasts (CAFs).
Transcriptional program eliciting TGF-b-induced EMT
Several transcription factors, including the zincnger factors Snail (also known as SNAI1) and Slug (SNAI2), the two-handed zinc-nger factors of dEF1 Suppression of the expression of Id2 mRNA is observed at 5 hours after the stimulation by TGF-b, preceding the repression of E-cadherin mRNA expression, and continues for more than 24 hours. E12 and E47, two alternatively spliced products of the E2A gene, are bHLH factors which induce a broblastic phenotype and suppress the expression of E-cadherin. Through constitutive association with E2A proteins, Id proteins maintain epithelial phenotypes by repressing the function of E2A.
dEF1 and SIP1 are the two-handed zinc-nger factors involved in EMT. 27),28) Levels of expression of dEF1 and SIP1 are gradually increased by TGF-b until 24 hours, with proles of expression reciprocal to that of E-cadherin in NMuMG cells. 24) dEF1 and SIP1 repress the transcription of E-cadherin through binding to the E-box region of the E-cadherin promoter. Smads interact with dEF1 and SIP1, and form repressor complexes on the E-cadherin promoter, 27),29) although binding of Smads to dEF1 and SIP1 appears not to be required for their repressor activity. 24) In contrast to the repression of Ecadherin, expression of mesenchymal markers, such as N-cadherin and bronectin, is not aected by SIP1 and dEF1 in NMuMG cells. 24) Snail and Slug are zinc-nger-containing tran- Snail suppresses E-cadherin expression by direct binding to the E2-box sequence of the E-cadherin promoter. 30) Snail interacts with transcriptional corepressor Sin3A, and histone deacetylase activity recruited to Snail is essential for repression of the Ecadherin mRNA expression. 34) SIP1 and Snail bind to partly overlapping E-cadherin promoter sequences. 27) Snail has also been shown to induce cell survival and movement, while it represses cell proliferation. In addition to TGF-b, Snail is induced by various extracellular signals, including those of the EGF and Notch pathways. 34) The activity of Snail is regulated by dierent phosphorylation events via various kinases, including GSK3b and p21-activated kinase-1 (PAK1). In addition, Snail protein is stabilized by tumor necrosis factor (TNF)-a through activation of the NF-B pathway. 35) LIV1, a breastcancer associated zinc transporter protein, is required for the nuclear localization of Snail. 36) The transcriptional program of the EMT inducers is regulated by certain upstream transcription factors (Fig. 3) . TGF-b induces the expression of Ets1, which functions as an upstream component of dEF1 and SIP1. Since Ets1 acts in cooperative fashion with the E2A proteins, Id proteins are also involved in the suppression of the TGF-b-induced up-regulation of dEF1 and SIP1. The high mobility group factor HMGA2 was identied as a new regulator of EMT. HMGA2 is induced by TGF-b-Smad signaling, and induces the expression of Snail, Slug, and Twist. 
Non-Smad signaling
Both Smad and non-Smad signaling appear to be important for full development of EMT (Fig. 1) . Although the involvement of Smad4 in EMT is controversial, key transcriptional events of EMT are mediated, at least in part, by the Smad signaling pathways. 20),40),41) Analyses of certain brotic diseases using Smad3-null mice have revealed the essential role of Smad3 in the process of EMT. 42) However, there is some evidence that non-Smad signaling also participates in the process of EMT. Direct interaction between the TGF-b receptors and the polarity complex that regulates epithelial polarization has been demonstrated. TbRI is localized in the tight junction through interaction with the PAK network and occludin. 43) Activated TbRII induces phosphorylation of the tight junction protein Par6, which in turn recruits Smurf1, an E3 ubiquitin ligase. Smurf1 then stimulates ubiquitylation and degradation of RhoA, leading to disorganization of tight junctions and loss of cell polarity.
Synergism between TGF-b and Ras signaling in EMT
Various signals, including integrin, Notch, Wnt, TNF-a, and EGF signals, have been reported to cooperate or synergize with TGF-b signaling and stimulate tumor invasion and metastasis. 2),22) Synergism between TGF-b and Ras signaling has been the most extensively investigated. Oft et al. 44) reported that when transformed by mutant Ras, mammary epithelial EpH4 cells undergo EMT by TGF-b1 and exhibit a broblast-like and invasive and metastatic phenotype resistant to the growth-inhibitory activity of TGF-b1. Using specic small-molecule inhibitors blocking the MAP kinase or PI3 kinase pathway, Janda et al. 
Endothelial-mesenchymal transition (EndMT)
Blood vessels are lined by endothelial cells and surrounded by mural cells (i.e. pericytes or smooth muscle cells). Endothelial cells have been shown to dierentiate into mesenchymal cells during development, and this process is termed endothelial-mesenchymal (or mural) transition (EndMT). 47) During the process of EndMT, expression of VE-cadherin, platelet-endothelial cell adhesion molecule 1 (PECAM1), and claudin-5 is reduced, while that of SMA and other mesenchymal markers is induced (Fig. 4) . Similar to EMT, EndMT is regulated by various signaling pathways, including TGF-b, Wnt, and Notch. Indeed, TGF-b is required at the onset of EndMT to initiate endocardial cushion tissue formation in mouse embryonic heart. 48 
Is MET inducible by TGF-b inhibition?
EMT is most often transient and reversible, and mesenchymal-epithelial transition (MET), the inverse process of EMT, occurs under certain physiological and pathological conditions. However, the signals that induce MET are largely unknown.
Thyroid transcription factor-1 (TTF-1, the product of Nkx2.1 gene) is a homeodomain-containing transcription factor, and serves as a master regulator for lung morphogenesis. 55) Frequent expression of it is reported in lung adenocarcinoma (72.1%), 56) and TTF-1 positivity has been reported to be a good prognostic marker in non-small cell lung cancer. 57) Saito et al. 58) reported that TTF-1 antagonizes TGF-b-induced EMT and restores epithelial phenotype in lung adenocarcinoma cells. TTF-1 antagonizes the eect of TGF-b, presumably through interaction with Smads, 59) and represses the expression of TGF-b-target genes, including Snail and Slug. Decrease in the expression of TTF-1 accelerates TGFb-induced EMT. Moreover, TGF-b represses the expression of TTF-1, and TTF-1 represses that of TGF-b2, the TGF-b isoform expressed in distal bronchial airway. 58) These ndings suggest that TTF-1 exhibits a tumor-suppressive eect with abrogation of response of adenocarcinoma cells to TGF-b, and that modulation of TTF-1 expression can be a novel therapeutic strategy for treatment of lung adenocarcinoma.
Inhibition of TGF-b signaling by TGF-b antagonists blocks EMT and induces MET, leading to prevention of cancer metastasis in vivo. JygMC(A) mouse mammary carcinoma cells spontaneously metastasize to lung and liver. Inhibition of TGF-b signaling by systemic administration of adenoviruses carrying Smad7 or c-Ski cDNA resulted in prevention of metastasis of JygMC(A) cells. 60) Interestingly, growth of primary tumors inoculated subcutaneously in mice was not signicantly aected by administration of Smad7-or c-Ski-adenoviruses. High-throughput Western blot analysis demonstrated increased expression of major components of adherens junctions and tight junctions, and decrease in migratory and invasive capacities of breast cancer cells infected with Smad7-adenovirus. 60) TGF-b also induces the survival of mammary carcinoma cells through expression of transcription factor DEC1, which is suppressed by TGF-b antagonists. 61) These ndings thus strongly suggest that inhibition of TGF-b signaling leads to prevention of cancer metastasis by inhibition of the process of EMT.
Conclusion and perspective
Several TGF-b antagonists, including smallmolecule inhibitors that inhibit the kinase activity of TbRI and monoclonal antibody to TGF-b, have been generated, and have been reported to inhibit metastasis of cancer through multiple mechanisms. 62)-64) Regulation of immune function and inhibition of EMT may be among the most important mechanisms for prevention of metastasis by TGF-b antagonists. 63),64) As described, recent ndings have suggested that TGF-b induces growth arrest and EMT through partially distinct pathways. It is thus important to discover new drug targets that block EMT, i.e. the tumor-progression arm of the TGF-b signaling pathway, without aecting its growth-inhibitory activity, i.e. the tumor-suppression arm.
